Overview

A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

Status:
Terminated

Trial end date:
2015-03-31

Target enrollment:

Participant gender:

Summary

KTx recipients receiving cyclosporine-based immunosuppressive therapy, and in the opinion of the investigator would benefit from switch to a tacrolimus-based immunosuppression, will switch the immunosuppressive therapy to a tacrolimus-based one. Efficacy and safety of patients will be observed for 52 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma China, Inc.

Treatments:

Cyclosporine
Cyclosporins
Tacrolimus